Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty
Osteoarthritis, Intraoperative Bleeding
About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Blood loss, transfusion rates, complications
Eligibility Criteria
Inclusion Criteria:
- Patients must be male or female of any race
- Ages 18-80 years old
- Patients must be undergoing an elective, primary knee arthroplasty
- Patients must be able to understand and willing to cooperate with study procedures
- Patients must be able to provide written and verbal informed consent
Exclusion Criteria:
- Allergy or intolerance to the study materials
- History of a venous thromboembolic event being treated with life-long anticoagulation
- Patients with a known congenital thrombophilia
- Patients who have had a venous thromboembolic event within the 12 months preceding surgery
- History of any substance abuse or dependence within the last 6 months
- Failure in collecting a required data point during study
- Those patients not indicated for knee replacement surgery including, pregnant women, those not cleared medically for the procedure and patients without significant radiographic evidence of degenerative joint disease.
- Patient using autologous blood transfusion
Sites / Locations
- Rush University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
Active Comparator
Active Comparator
Active Comparator
No Intervention
Females receiving a uniform dose of TA
Weighted dose of TA in female patients
Tranexamic acid weighted dose male
Uniform single dose TA male patient
Historical Cohort
Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
25 patients with no TA use in their surgical history. A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651.